drugset

drugset / Trial / NCT01861197

Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

NCT01861197 ↗

Phase 2 Unknown 27 enrolled Samsung Medical Center

NaSingle-groupOpen-labelTreatment

Summary

Efficacy of Dovitinib for Squamous NSCLC.

Timeline

Start: 2013-03
Primary completion: 2015-01
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dovitinib	Small molecule	500 mg	—

Indications